Joint project Actiheal
As part of the Actiheal joint project, innovative technologies for activation and application of tissue and cells for the treatment of chronic wounds are being developed.
The aim of the project is the biomodulation and clinical application of regenerative cells of the stromal vascular fraction for the treatment of chronic wounds, which occur, for example, in patients with diabetes (diabetic foot). These treatments should make it possible to noticeably improve the quality of life of the patients and to prevent the complications typical of diabetes.
For this purpose, mesenchymal stem cells are extracted from human adipose tissue (adipose derived mesenchymal stem cells, adMSC). The stem cells are then irradiated using near-infrared to infrared light (low-level light therapy, LLLT) or flowed through with cold atmospheric plasma and applied autologically. The processes of biomodulation are said to result in an increase in the proliferation (multiplication of cells by cell division) of the stem cells and thus to improve wound healing.
In this joint project, the Chair of Microfluidics at the University of Rostock is responsible for the subproject for the development, production and optimization of microchannel cassettes for photobiomodulation and plasmabiomodulation of cell suspensions and microtissue clusters from human adipose tissue. The cartridge prototypes are manufactured using additive manufacturing processes of biocompatible materials, which enables a fast optimization process.
Contact: Mario Thürling M.Sc. (parental leave); Florian Neukirch M.Sc.
Duration: 09/2019 – 06/2023
Funded by: Ministerium für Wirtschaft, Bau und Tourismus (M-V), Operationelles Programm für den Europäischen Fonds für regionale Entwicklung in Mecklenburg-Vorpommern in der Förderperiode 2014 bis 2020 (EFRE-OP M-V)
Human Med AG, Schwerin
Department of Cell Biology, University Medicine Rostock
Competence Center Diabetes, Klinikum Karlsburg